The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells

Leukemia. 2008 Mar;22(3):635-8. doi: 10.1038/sj.leu.2404922. Epub 2007 Sep 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Apoptosis / drug effects
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Crotonates / pharmacology
  • Cyclin A / metabolism
  • Cyclin D3
  • Cyclin-Dependent Kinase 2 / antagonists & inhibitors
  • Cyclins / metabolism
  • DNA Replication / drug effects
  • Drug Screening Assays, Antitumor
  • G1 Phase / drug effects*
  • Humans
  • Immunologic Factors / pharmacology*
  • Isoxazoles / pharmacology*
  • Leflunomide
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Neoplasm Proteins / antagonists & inhibitors
  • Oxidoreductases Acting on CH-CH Group Donors / antagonists & inhibitors
  • Phosphorylation / drug effects
  • Prodrugs / pharmacology
  • Protein Processing, Post-Translational / drug effects
  • Receptors, Immunologic / antagonists & inhibitors
  • Receptors, Prostaglandin / antagonists & inhibitors
  • Retinoblastoma Protein / metabolism
  • Toluidines / pharmacology
  • Tumor Cells, Cultured / drug effects
  • ZAP-70 Protein-Tyrosine Kinase / analysis

Substances

  • CCND3 protein, human
  • Crotonates
  • Cyclin A
  • Cyclin D3
  • Cyclins
  • Immunologic Factors
  • Isoxazoles
  • Neoplasm Proteins
  • Prodrugs
  • Receptors, Immunologic
  • Receptors, Prostaglandin
  • Retinoblastoma Protein
  • Toluidines
  • teriflunomide
  • Oxidoreductases Acting on CH-CH Group Donors
  • dihydroorotate dehydrogenase
  • ZAP-70 Protein-Tyrosine Kinase
  • ZAP70 protein, human
  • CDK2 protein, human
  • Cyclin-Dependent Kinase 2
  • Leflunomide
  • prostaglandin D2 receptor